Orforglipron: Complete Evidence Review (2026)

Last updated: June 2026

Medical disclaimer: This article is for informational purposes only and is not medical advice. Orforglipron (brand name Foundayo) was approved by the FDA for chronic weight management in April 2026; it is not a substitute for a conversation with your own clinician. Do not start, stop, or change any treatment based on what you read here. Consult your doctor.

Orforglipron is a once-daily GLP-1 pill from Eli Lilly. Unlike older injectable drugs, it is a small molecule, so it survives the gut and can be taken any time of day. This review pulls the real trial numbers from the ACHIEVE diabetes program and the ATTAIN obesity program, with every figure cited to a primary source.

What is orforglipron and how does it work?

Orforglipron is an oral, non-peptide GLP-1 receptor agonist. It mimics the gut hormone GLP-1, which tells your brain you are full and helps your pancreas release insulin. Because it is a small molecule and not a peptide, it does not break down in the stomach the way injectable GLP-1 drugs would.

That chemistry is the whole story. Semaglutide and tirzepatide are peptides, so they need a shot or a strict empty-stomach oral routine. Orforglipron does not. You can swallow it with or without food, any time of day (Eli Lilly, 2026).

The drug's research code was LY3502970. Lilly studied it across two big Phase 3 programs: ACHIEVE for type 2 diabetes and ATTAIN for obesity. You can see where it sits among the new drugs in our next-gen GLP-1 pipeline overview.

Why does the small-molecule design matter so much? Peptide drugs are fragile. Stomach acid and enzymes chew them up, which is why semaglutide needs either an injection or a tightly controlled empty-stomach pill. A small molecule like orforglipron is stable, so it absorbs reliably no matter what you ate.

That stability also makes the drug cheaper to make at scale. A pill produced by standard chemistry is far easier to manufacture than a peptide grown in cells. That production edge is part of why analysts expect oral GLP-1 access to widen (Eli Lilly, 2026).

How much weight loss did orforglipron produce in trials?

At the top 36 mg dose, orforglipron produced an average weight loss of about 11.2% over 72 weeks in people with obesity but no diabetes. That came from ATTAIN-1, the largest obesity trial. People with both obesity and diabetes lost slightly less, around 10.5%, in ATTAIN-2.

Here is the headline efficacy data, broken out by dose and by patient group.

Trial (population)	Dose	Mean weight loss	Placebo	Duration	Source
ATTAIN-1 (obesity, no T2D)	6 mg	-7.5%	-2.1%	72 wk	NEJM 2025
ATTAIN-1 (obesity, no T2D)	12 mg	-8.4%	-2.1%	72 wk	NEJM 2025
ATTAIN-1 (obesity, no T2D)	36 mg	-11.2%	-2.1%	72 wk	NEJM 2025
ATTAIN-2 (obesity + T2D)	36 mg	-10.5%	-2.2%	72 wk	Lancet 2025
ACHIEVE-1 (T2D)	36 mg	-7.6%	-1.7%	40 wk	NEJM 2025

The dose response is clear. More drug means more weight loss, and the jump from 12 mg to 36 mg is the biggest step (NEJM ATTAIN-1, 2025).

The diabetes groups lost less weight than the obesity-only groups. That pattern is common with GLP-1 drugs. People with type 2 diabetes tend to shed fewer pounds on the same dose (Lilly ATTAIN-2 release, 2025).

It also helps to look past the average. In the ATTAIN-1 36 mg group, 54.6% of people lost at least 10% of their body weight. More than a third (36.0%) lost at least 15%, and 18.4% lost 20% or more (ACC ATTAIN-1 summary, 2025).

Weight-loss threshold (ATTAIN-1, 36 mg)	Orforglipron	Placebo
Lost ≥10% of body weight	54.6%	12.9%
Lost ≥15% of body weight	36.0%	5.9%
Lost ≥20% of body weight	18.4%	2.8%

So the average hides a wide range. Some people barely moved. Others lost a fifth of their starting weight.

It helps to ground these percentages in pounds. In the ATTAIN-2 trial, people with obesity and diabetes on the 36 mg dose lost an average of 22.9 lbs. The placebo group lost about 5.1 lbs over the same 72 weeks (Lilly ATTAIN-2 release, 2025).

The weight-loss curve had not fully flattened by the end of the trials. That hints there may be more to come past 72 weeks, though no published data confirms it yet (NEJM ATTAIN-1, 2025).

One more subgroup note. ATTAIN-1 enrolled a diverse group: 64% women, 57% White, 29% Asian, with a mean age of 45. The weight-loss benefit held across these groups, though the trial was not powered to compare them head to head (Weill Cornell, 2025).

How well did orforglipron control blood sugar (A1C)?

In the ACHIEVE-1 diabetes trial, orforglipron lowered A1C by 1.2% to 1.5% over 40 weeks, versus 0.4% for placebo. Patients started with an average A1C of 8.0%. The drug brought most of them close to or below the diabetes line.

Here is the A1C data by dose from ACHIEVE-1.

Dose	A1C reduction (40 wk)	Source
3 mg	-1.2%	NEJM 2025
12 mg	-1.5%	NEJM 2025
36 mg	-1.5%	NEJM 2025
Placebo	-0.4%	NEJM 2025

A key secondary result stood out. More than 65% of people on the highest dose reached an A1C of 6.5% or lower, which is under the American Diabetes Association threshold for diabetes (Lilly ACHIEVE-1 release, 2025).

The subgroup picture matters here. People with diabetes (ACHIEVE-1, ATTAIN-2) saw strong A1C drops, with the deepest cut of about 1.8% in ATTAIN-2. People without diabetes were not the focus of A1C analysis, since their blood sugar was already normal (NEJM full Phase 3 results, 2025).

Baseline A1C shaped the result too. ACHIEVE-1 enrolled people with an average starting A1C of 8.0%, which is solidly in the diabetes range. People who start higher tend to have more room to drop, so the 1.5% figure reflects a fairly elevated group (Lilly ACHIEVE-1 release, 2025).

The diabetes data did not stop at one trial. Lilly later reported that orforglipron beat oral semaglutide on A1C in a head-to-head study, and additional ACHIEVE trials confirmed the glycemic effect. The signal across the program is consistent, not a one-off (Lancet head-to-head, 2025).

What are orforglipron's side effects?

The most common side effects were gastrointestinal: nausea, vomiting, diarrhea, and constipation. Most were mild to moderate and showed up during the dose-increase phase. The rates rose with higher doses, which is the same pattern seen with injectable GLP-1 drugs.

Here is the side-effect data from ATTAIN-1, broken out by dose.

Side effect (ATTAIN-1)	6 mg	12 mg	36 mg	Placebo
Nausea	28.9%	35.9%	33.7%	10.4%
Vomiting	13.0%	21.4%	24.0%	3.5%
Diarrhea	21.0%	22.8%	23.1%	9.6%
Constipation	21.7%	29.8%	25.4%	9.3%

Source: Lilly ATTAIN-1 NEJM release, 2025.

Some people stopped the drug because of these effects. In ATTAIN-1, discontinuation due to side effects ran 5.3% at 6 mg, 7.9% at 12 mg, and 10.3% at 36 mg, against 2.7% on placebo (Lilly ATTAIN-1 release, 2025).

The drop-out pattern is worth a pause. The benefit climbs with dose, but so does the share of people who quit. That trade-off is part of why doctors step the dose up slowly (ClinicalTrials.gov NCT05869903, 2025).

Beyond the gut, orforglipron also improved blood pressure, waist size, and cholesterol markers across all doses. Those cardiometabolic gains tracked with the weight loss (Lilly ATTAIN-2 release, 2025).

How a person starts the drug shapes the side-effect load. Trials used a slow dose-escalation schedule, raising the dose in steps over weeks rather than starting high. Most nausea and vomiting clustered in that ramp-up window and eased once the dose stabilized (NEJM ATTAIN-1, 2025).

Lilly's overall framing was that the safety profile looked consistent with injectable GLP-1 medicines. That is a meaningful claim, since it means swapping the needle for a pill did not introduce a new safety surprise in these trials (Lilly Phase 3 safety release, 2025).

How does oral orforglipron compare to injectable GLP-1s?

Orforglipron's weight loss (about 11% at 72 weeks) lands below the best injectables, but it is a pill with no food or water rules. Tirzepatide and high-dose semaglutide have produced larger average losses in their own trials. Orforglipron trades some peak efficacy for the ease of a daily tablet.

There is also a direct head-to-head signal. In a diabetes trial, oral orforglipron beat oral semaglutide (Rybelsus) on both blood sugar and weight (Lancet head-to-head, 2025).

Keep one caveat in mind. That comparison was against the oral form of semaglutide, not the injectable. Cross-trial comparisons against injectable semaglutide or tirzepatide are not apples to apples, because the trials enrolled different people and ran for different lengths. The honest read is that orforglipron is competitive among pills and somewhat behind the strongest injectables on raw weight loss (NEJM ATTAIN-1, 2025).

The convenience gap is real for many patients. Injections require refrigeration, careful technique, and weekly timing. A pill removes all three hurdles. For people who avoid GLP-1 drugs purely because of needles, orforglipron changes the math (Eli Lilly FDA approval release, 2026).

Cost is the other axis. As an orally manufactured small molecule, orforglipron may scale more cheaply than peptide injectables, though final pricing depends on insurance and the manufacturer. For a full side-by-side breakdown of doses, costs, and outcomes, see our oral vs injectable GLP-1 comparison. You can also browse the broader class on our medications page.

Where is orforglipron in the FDA approval process?

The FDA approved orforglipron, sold as Foundayo, for chronic weight management on April 1, 2026. It is the first oral small-molecule GLP-1 pill cleared for weight loss, and it can be taken any time of day without food or water limits.

The approval covers adults with obesity, or adults who are overweight with at least one weight-related condition, alongside diet and exercise (Eli Lilly FDA approval release, 2026).

The official prescribing information is public. You can read the FDA-approved label for dosing, warnings, and contraindications (FDA Foundayo label, 2026).

A diabetes indication is a separate question. The ACHIEVE program supports use in type 2 diabetes, and Lilly has pursued regulatory filings, but always check the current label for the approved uses where you live.

The path to approval was unusually fast for the obesity drug class. Lilly reported its first Phase 3 obesity readout in 2025, published the full data in major journals, and reached FDA clearance by April 2026 (Patient Care Online, 2026).

Approval in one country does not mean approval everywhere. Regulators in other regions review on their own timelines, so the drug's status outside the United States may differ. The official FDA label is the source of truth for U.S. patients (FDA Foundayo label, 2026).

What does the evidence NOT yet support?

The trials ran for 40 to 72 weeks, so the long-term data is still thin. We do not yet have multi-year results showing whether the weight loss holds, whether the safety signal stays clean, or what happens when people stop the drug.

A few specific gaps stand out:

• Durability. No published trial follows patients for several years, so weight regain after stopping is not well measured (ClinicalTrials.gov NCT05872620, 2025).
• Head-to-head depth. Orforglipron beat oral semaglutide in one trial, but there is no large head-to-head against tirzepatide or injectable semaglutide on weight loss.
• Cardiovascular outcomes. The drug improved risk markers like blood pressure and cholesterol, but no trial has yet proven it prevents heart attacks or strokes (Lilly ATTAIN-2 release, 2025).
• Special populations. Data in older adults, people with kidney or liver disease, and pregnancy is limited.

There is also the question of weight regain. With other GLP-1 drugs, stopping the medication often brings much of the weight back. No published orforglipron trial has yet tracked what happens after people stop, so we cannot say whether this pill behaves differently (NEJM ATTAIN-1, 2025).

Real-world adherence is another unknown. Trial participants get close monitoring and support. A daily pill taken at home, without that structure, may produce different results than the controlled studies suggest.

Honest reading: the short-to-medium term evidence is strong and consistent. The long game is still being written. Treat the trial numbers as a solid starting point, not a final word, and let your clinician weigh them against your own health picture.

Frequently Asked Questions

How much weight can you lose on orforglipron?

In the ATTAIN-1 obesity trial, people on the highest 36 mg dose lost an average of 11.2% of their body weight over 72 weeks, versus 2.1% on placebo. Results varied widely between people. More than half lost at least 10%, while about 18% lost 20% or more.

Is orforglipron FDA-approved?

Yes. The FDA approved orforglipron under the brand name Foundayo for chronic weight management on April 1, 2026. It is approved for adults with obesity, or overweight adults with a weight-related condition, used with diet and exercise. Always confirm the current approved uses on the official label.

What are the most common side effects of orforglipron?

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. In trials, nausea hit about 29% to 36% of people depending on dose, versus around 10% on placebo. Most cases were mild to moderate and happened during the dose-increase phase.

How is orforglipron different from Ozempic or Wegovy?

Orforglipron is a once-daily pill, while Ozempic and Wegovy (semaglutide) are weekly injections. Orforglipron is also a small molecule, so it can be taken any time with or without food. Average weight loss in trials was somewhat lower than top injectables, but it avoids needles and food-timing rules.

How does orforglipron lower blood sugar?

Orforglipron activates the GLP-1 receptor, which prompts the pancreas to release insulin when blood sugar rises and slows the release of glucose from the liver. In the ACHIEVE-1 diabetes trial, it lowered A1C by 1.2% to 1.5% over 40 weeks. More than 65% of people on the top dose reached an A1C at or below 6.5%.

Related Reading

• Retatrutide: complete evidence review
• Oral vs injectable GLP-1: orforglipron vs the injectables
• Next-gen GLP-1 pipeline 2026: the landscape

-- The GLP-1 Daily Team